

FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

I am researching the incidence and treatment of breast cancer. I would greatly appreciate if you could answer the following questions

- How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:**

• Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	33
• Abemaciclib + Fulvestrant	0
• Alpelisib + Fulvestrant	2
• Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide only	10
• Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel	0
• Atezolizumab	0
• Capivasertib	1
• Capecitabine as a single agent	23
• Carboplatin + Paclitaxel	3
• Elacestrant	5
• Eribulin as a single agent or in combination	1
• Everolimus + Exemestane	0
• Fulvestrant as a single agent	
• Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	7
• Palbociclib + Fulvestrant	14
• Parp Inhibitors (Olaparib/Talazoparib)	0
• Pembrolizumab Monotherapy	3
• Pembrolizumab + Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide	3

• Carboplatin + Paclitaxel + Pembrolizumab	2
• Pertuzumab (Perjeta) + Trastuzumab (Herceptin)	1
• Phesgo (Pertuzumab + Trastuzumab in a single injection)	38
• Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	54
• Ribociclib + Fulvestrant	23
• Sacituzumab Govitecan	1
• Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent	7
• Trastuzumab deruxtecan (Enhertu)	2
• Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel	33
• Trastuzumab emtansine (Kadcyla)	8
• Any other active systemic anti-cancer therapy	15

2. In the past 3 months, how many patients have been treated with the following systemic anti-cancer therapies for breast cancer (please indicate whether they were treated for early or metastatic disease):

	Total Patients	Early Patients	Metastatic Patients
Phesgo (Pertuzumab + Trastuzumab in a single injection)	38	13	25
Pertuzumab (Perjeta) + Trastuzumab (Herceptin)	1	1	0
Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel	33	24	9
Trastuzumab deruxtecan (Enhertu)	2	0	2
Trastuzumab emtansine (Kadcyla)	8	5	3
Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	33	30	3
Abemaciclib + Fulvestrant	0	0	0
Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	54	20	34
Ribociclib + Fulvestrant	23	1	22
Capecitabine as a single agent	23	7	16
Carboplatin + Paclitaxel	3	3	0
Carboplatin + Paclitaxel + Pembrolizumab	2	2	0

3. Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part.

Yes, please see attached document - '26-097 - Clinical Trials for Breast Cancer'.

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, you have the right to request an internal review. Please write to the Freedom of Information Department (esh-tr.foi@nhs.net), quoting the above reference, within 40 working days. The Trust is not obliged to accept an internal review after this date.

Should you still be dissatisfied with your FOI request, you have the right of complaint to the Information Commissioner at the following address:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire SK9 5AF

Telephone: 0303 123 1113

Yours sincerely

Freedom of Information Department
esh-tr.foi@nhs.net

FOI 26/097 - East Sussex Healthcare NHS Trust

SWITCH	Understanding side effects experienced by women prescribed hormone therapy (SWITCH)	IRAS 329586	Open to recruitment	42 patients recruited
Add Aspirin Breast Cohort	A phase III double-blind placebo-controlled randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours.	IRAS 120104	Closed to recruitment, patients in follow up	18 breast cohort patients recruited
POSNOC	POSNOC - POSitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy. A randomised controlled trial of axillary treatment in women with early stage breast cancer who have metastases in one or two sentinel nodes.	IRAS 137785	Closed to recruitment, patients in follow up	23 patients recruited
OPTIMA	Optimal Personalised Treatment of early breast cancer using Multiparameter Analysis	IRAS	Closed to recruitment, patients in follow up	4 patients recruited